Donepezil found helpful in dementia with lewy bodies

July 31, 2012
Donepezil found helpful in dementia with lewy bodies
For patients with dementia with Lewy bodies, treatment with 5 or 10 mg/day donepezil is associated with significant cognitive, behavioral, and global function improvements, according to research published in the July issue of the Annals of Neurology.

(HealthDay) -- For patients with dementia with Lewy bodies (DLB), treatment with 5 or 10 mg/day donepezil is associated with significant cognitive, behavioral, and global function improvements, according to research published in the July issue of the Annals of Neurology.

Etsuro Mori, M.D., Ph.D., of the Tohoku University Graduate School of Medicine in Sendai, Japan, and colleagues conducted a randomized, double-blind, placebo-controlled trial involving 140 patients with DLB who received either placebo or 3, 5, or 10 mg of donepezil hydrochloride per day for 12 weeks (35, 35, 33, and 37 patients, respectively). Cognitive function was measured using the Mini-Mental State Examination (MMSE); were measured using the Neuropsychiatric Inventory; global function was evaluated using the Clinician's Interview-Based Impression of Change-plus Caregiver Input (CIBIC-plus); and caregiver burden was also assessed.

The researchers found that, compared with , the MMSE scores were significantly better with donepezil 5 mg (mean difference, 3.8) and 10 mg (mean difference, 2.4), but the 3 mg/day dose was not significantly better than placebo (P = 0.017). Donepezil at doses of 3, 5, and 10 mg/day correlated with significant improvements versus on CIBIC-plus. Both the 5 and 10 mg doses of donepezil resulted in significant improvements in . Caregiver burden also improved, but only with the 10 mg/day dose. The safety results were similar among the groups and were consistent with the known profile.

"Donepezil at 5 and 10 mg/day produces significant cognitive, behavioral, and global improvements that last at least 12 weeks in DLB patients, reducing caregiver burden at the highest dose," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Eisai Co., which funded the study and manufactures donepezil.

Explore further: Sumatriptan/Naproxen helpful in treating teens' migraines

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Sumatriptan/Naproxen helpful in treating teens' migraines

May 15, 2012
(HealthDay) -- Treatment with sumatriptan and naproxen sodium (suma/nap) is well tolerated and effective in reducing migraine pain in adolescents, according to a study published online May 14 in Pediatrics.

Prophylaxis with apixaban feasible for cancer patients

March 29, 2012
(HealthDay) -- Primary venous thromboembolism prophylaxis with apixaban, an oral direct Factor Xa inhibitor, in ambulatory cancer patients undergoing first- or second-line chemotherapy for advanced or metastatic cancer, is ...

ECO: New weight loss drug effective in advanced obesity

May 14, 2012
(HealthDay) -- A new combination treatment of controlled-release phentermine/topiramate (PHEN/TPM CR) leads to significantly greater weight loss than a placebo even in individuals with significant obesity-related comorbidities, ...

Experts challenge FDA over approval for new dose of Alzheimer's drug

March 22, 2012
Approval for a new dose of a best-selling Alzheimer's drug "breached the FDA's own regulatory standard" and has led to "incomplete and distorted messages" about the drug, warn experts in the British Medical Journal today.

Belimumab deemed safe for long-term lupus treatment

June 19, 2012
(HealthDay) -- For patients with systemic lupus erythematosus (SLE), long-term belimumab therapy combined with standard therapy is well tolerated, according to a study published online June 5 in Arthritis & Rheumatism.

Vandetanib doesn't up survival in non-small-cell lung cancer

March 2, 2012
(HealthDay) -- Vandetanib does not improve overall survival for patients who have received previous treatment for advanced non-small-cell lung cancer (NSCLC), according to a study published online Feb. 27 in the Journal of ...

Recommended for you

Mechanism behind neuron death in motor neurone disease and frontotemporal dementia discovered

April 20, 2018
Scientists have identified the molecular mechanism that leads to the death of neurons in amyotrophic lateral sclerosis (also known as ALS or motor neurone disease) and a common form of frontotemporal dementia.

When there's an audience, people's performance improves

April 20, 2018
Often, people think performing in front of others will make them mess up, but a new study led by a Johns Hopkins University neuroscientist found the opposite: being watched makes people do better.

Signaling between neuron types found to instigate morphological changes during early neocortex development

April 20, 2018
A team of researchers from several institutions in Japan has found that developing neocortex neurons in mammals undergo a morphological transition from a multipolar shape to a bipolar shape due at least partially to signaling ...

MRI technique detects spinal cord changes in MS patients

April 20, 2018
A Vanderbilt University Medical Center-led research team has shown that magnetic resonance imaging (MRI) can detect changes in resting-state spinal cord function in patients with multiple sclerosis (MS).

Gene variant increases empathy-driven fear in mice

April 20, 2018
Researchers at the Center for Cognition and Sociality, within the Institute for Basic Science (IBS), have just published as study in Neuron reporting a genetic variant that controls and increases empathy-driven fear in mice. ...

Scientists identify connection between dopamine and behavior related to pain and fear

April 19, 2018
Scientists at the University of Maryland School of Medicine have for the first time found direct causal links between the neurotransmitter dopamine and avoidance—behavior related to pain and fear.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.